Scott, Frank I <br/><br/>
Identification of the Most Cost-effective Position of Vedolizumab Among the Available Biologic Drugs for the Treatment of Ulcerative Colitis.  [electronic resource] 

 -  Journal of Crohn's & colitis  Jun 2020 
 - 575-587 p.  digital 
<br/><br/> Publication Type: Journal Article 
<br/><br/><label>ISSN: </label>1876-4479 
<br/><br/><label>Standard No.: </label>10.1093/ecco-jcc/jjz212  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adalimumab--therapeutic use<br/>Adult<br/>Algorithms<br/>Antibodies, Monoclonal, Humanized--administration & dosage<br/>Azathioprine--therapeutic use<br/>Biological Products--economics<br/>Colectomy<br/>Colitis, Ulcerative--drug therapy<br/>Cost-Benefit Analysis--statistics & numerical data<br/>Drug Therapy, Combination<br/>Gastrointestinal Agents--administration & dosage<br/>Humans<br/>Immunosuppressive Agents--therapeutic use<br/>Infliximab--therapeutic use<br/>Male<br/>Markov Chains<br/>Models, Economic<br/>Quality-Adjusted Life Years<br/>Tumor Necrosis Factor-alpha--antagonists & inhibitors